PARP1 and ovarian carcinoma: Our experimental results prompted us to speculate whether the defective cellular HR repair capacity induced by MEnZn‐CuO NPs would enhance the sensitivity of ovarian cancer cell lines to PARP inhibitors in a synthetic lethal manner.